A randomised controlled Trial of high and low dose Avastin® for Neovascular macular Degeneration in the East Midlands (TANDEM)

ottingham University Hospitals NHS Trust (UK)0 sites812 target enrollmentSeptember 22, 2009

Overview

Registry

who.int

Start Date

September 22, 2009

End Date

March 31, 2017

Last Updated

5 years ago

Study Type

Interventional

Sex

All

Sponsor

ottingham University Hospitals NHS Trust (UK)

•1\. Adults of either sex aged 50 years and older
•2\. Newly referred for the treatment of nAMD
•3\. Corrected distance logarithm of the minimum angle of resolution visual acuity (VAlogMAR) greater than or equal to 20 letters and less than 70 letters read on a standard ETDRS chart at 1 metre
•4\. Any component of the neovascular lesion (choroidal neovascularisation \[CNV], blood, serous pigment epithelial detachment, elevated blocked fluorescence) involving the centre of the fovea

•1\. Aged less than 50 years
•2\. Corrected VAlogMAR less than 20 letters at 1 metre
•3\. Long standing CNV evidenced by the presence of fibrosis in excess of 50% of the total lesion
•4\. Greatest linear diameter greater than 6000 µm (equivalent to about 12 disc diameters)
•5\. Argon laser treatment to the proposed study eye within the last 6 months
•6\. Presence of thick blood involving the centre of the fovea
•7\. Presence of other active ocular disease causing concurrent vision loss, e.g. diabetic retinopathy
•8\. Previous treatment with photodynamic therapy (PDT) or a vascular endothelial growth factor (VEGF) inhibitor in either eye
•9\. Patients with 8 or more diopters of myopia
•10\. Pregnant and or lactating women